Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unexpectedly positive Amgen reports 34% EPS growth with Q2 revenue up 13%

This article was originally published in Scrip

Executive Summary

Amgen's stock price shot past the high end of its 52-week range in after-hours trading on 26 July when it announced year-over-year gains of 13% for second quarter 2012 revenue and 8% for product sales as well as a 34% jump in adjusted earnings per share (EPS) as the company prepares to step up R&D spending for later-stage assets in the pipeline.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts